Index RUT
P/E 92.90
EPS (ttm) 0.34
Insider Own 0.82%
Shs Outstand 48.84M
Perf Week -3.17%
Market Cap 1.53B
Forward P/E 39.30
EPS next Y 0.79
Insider Trans 0.77%
Shs Float 48.78M
Perf Month -14.39%
Income 16.61M
PEG 3.10
EPS next Q 0.19
Inst Own 96.42%
Short Float 8.02%
Perf Quarter -23.10%
Sales 332.94M
P/S 4.60
EPS this Y -27.67%
Inst Trans 2.11%
Short Ratio 5.25
Perf Half Y -11.36%
Book/sh 8.32
P/B 3.74
EPS next Y 8.40%
ROA 3.49%
Short Interest 3.91M
Perf Year -24.67%
Cash/sh 4.78
P/C 6.51
EPS next 5Y 30.00%
ROE 4.36%
52W Range 26.66 - 52.68
Perf YTD -0.29%
Dividend Est. -
P/FCF 112.97
EPS past 5Y 31.51%
ROI 3.77%
52W High -40.93%
Beta 0.60
Dividend TTM -
Quick Ratio 5.21
Sales past 5Y 21.55%
Gross Margin 79.24%
52W Low 16.75%
ATR (14) 1.82
Dividend Ex-Date -
Current Ratio 5.80
EPS Y/Y TTM -34.15%
Oper. Margin 7.90%
RSI (14) 32.65
Volatility 3.95% 5.34%
Employees 1115
Debt/Eq 0.09
Sales Y/Y TTM 8.83%
Profit Margin 4.99%
Recom 1.93
Target Price 50.28
Option/Short Yes / Yes
LT Debt/Eq 0.08
EPS Q/Q 20.90%
Payout 0.00%
Rel Volume 1.03
Prev Close 31.20
Sales Surprise 3.98%
EPS Surprise 63.25%
Sales Q/Q 7.26%
Earnings Aug 07 AMC
Avg Volume 744.55K
Price 31.12
SMA20 -10.84%
SMA50 -21.57%
SMA200 -17.33%
Trades
Volume 769,669
Change -0.26%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-15-24 Downgrade
Morgan Stanley
Equal-Weight → Underweight
$50 → $37
Jun-11-24 Upgrade
BTIG Research
Neutral → Buy
$46
Mar-11-24 Upgrade
Stifel
Hold → Buy
$30 → $50
Dec-05-23 Downgrade
Needham
Buy → Hold
Dec-04-23 Initiated
Morgan Stanley
Equal-Weight
$35
Sep-15-23 Downgrade
The Benchmark Company
Buy → Hold
Aug-03-23 Downgrade
Canaccord Genuity
Buy → Hold
$77 → $48
Jun-07-23 Downgrade
William Blair
Outperform → Mkt Perform
Apr-17-23 Initiated
Piper Sandler
Neutral
$65
Feb-06-23 Downgrade
BTIG Research
Buy → Neutral
Dec-28-22 Reiterated
BTIG Research
Buy
$80 → $67
Dec-08-22 Initiated
Stifel
Hold
$60
Nov-07-22 Upgrade
Sidoti
Neutral → Buy
Oct-14-22 Resumed
Stephens
Overweight
$91
Oct-13-22 Initiated
Mizuho
Buy
$85
Apr-08-22 Initiated
Needham
Buy
$87
Mar-28-22 Upgrade
The Benchmark Company
Hold → Buy
$97
Mar-18-22 Upgrade
BTIG Research
Neutral → Buy
$98
Jul-09-21 Initiated
Oppenheimer
Perform
$150
Jan-19-21 Downgrade
The Benchmark Company
Buy → Hold
Show Previous Ratings
Sep-06-24 01:01PM
Aug-13-24 10:48AM
Aug-12-24 09:15AM
Aug-07-24 11:53PM
08:00PM
05:20PM
Loading…
05:20PM
04:22PM
(Associated Press Finance)
04:01PM
Jul-31-24 07:00AM
Jul-30-24 07:00AM
Jun-27-24 01:25PM
(Investor's Business Daily)
04:01AM
Jun-05-24 07:00AM
May-13-24 11:06AM
May-08-24 11:06AM
10:17AM
Loading…
10:17AM
07:59AM
03:43AM
May-07-24 11:54PM
07:30PM
05:58PM
05:26PM
(Associated Press Finance)
04:03PM
04:01PM
May-06-24 09:16AM
May-01-24 07:00AM
Apr-29-24 07:00AM
Apr-25-24 03:43PM
(Investor's Business Daily)
Apr-05-24 09:15AM
Apr-04-24 04:26PM
(Investor's Business Daily) +16.48%
03:54PM
Loading…
03:54PM
07:00AM
Apr-02-24 07:00AM
Mar-26-24 11:45AM
Mar-20-24 04:22AM
Mar-18-24 07:00AM
Mar-12-24 10:30AM
07:00AM
Mar-06-24 07:00AM
Feb-28-24 10:58AM
Feb-27-24 02:00PM
Feb-26-24 05:30PM
04:39PM
(Associated Press Finance)
04:34PM
04:01PM
Feb-19-24 07:00AM
Jan-27-24 01:03PM
Jan-23-24 07:00AM
Jan-12-24 06:49PM
Jan-08-24 07:00AM
Dec-17-23 12:35PM
Dec-05-23 03:16AM
Dec-04-23 04:05PM
Nov-15-23 07:00AM
Nov-02-23 05:50PM
09:23AM
(Thomson Reuters StreetEvents)
Nov-01-23 06:30PM
05:56PM
04:17PM
(Associated Press Finance)
04:01PM
Oct-31-23 04:40PM
Oct-18-23 04:05PM
Oct-17-23 07:00AM
Oct-13-23 06:30PM
Oct-10-23 10:51AM
Sep-19-23 11:51AM
Sep-15-23 09:32AM
Sep-14-23 12:53PM
07:00AM
Sep-08-23 11:38AM
Sep-07-23 05:00PM
Aug-18-23 10:40AM
Aug-17-23 06:48PM
Aug-09-23 07:00AM
Aug-07-23 07:00AM
05:00AM
Aug-03-23 07:18PM
Aug-02-23 05:25PM
04:21PM
04:01PM
Jul-19-23 07:00AM
Jun-21-23 08:00PM
Jun-13-23 08:00AM
May-26-23 06:00AM
May-17-23 10:10AM
May-09-23 01:48PM
May-04-23 07:00AM
May-03-23 05:35PM
04:29PM
04:01PM
Apr-27-23 10:02AM
Apr-26-23 08:00PM
10:02AM
Apr-23-23 08:25AM
Apr-19-23 07:00AM
Apr-07-23 11:44AM
Apr-04-23 06:00PM
Mar-29-23 06:00PM
07:00AM
Mar-23-23 06:00PM
STAAR Surgical Co. engages in the design, development, manufacture, and sale of ophthalmic surgical products. The firm offers implantable lenses for the eye and accessory delivery systems. Its products include refractive and cataract solutions through the Collamer brand. The company was founded in 1982 and is headquartered in Lake Forest, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Butcher Arthur C Director Aug 12 '24 Buy 37.99 1,315 49,957 4,208 Aug 19 05:31 PM BROADWOOD PARTNERS, L.P. 10% Owner May 09 '24 Buy 42.56 1 43 10,768,431 May 13 06:00 PM WEISNER AIMEE S Director Mar 14 '24 Buy 38.11 1,750 66,692 10,864 Mar 14 05:23 PM Williams Patrick F. Chief Financial Officer Mar 07 '24 Option Exercise 0.00 2,614 0 45,475 Mar 11 06:06 AM BROADWOOD PARTNERS, L.P. 10% Owner Jan 08 '24 Buy 27.11 4,042 109,570 10,768,430 Jan 10 05:44 PM BROADWOOD PARTNERS, L.P. 10% Owner Jan 05 '24 Buy 28.48 156,734 4,463,231 10,764,388 Jan 05 07:07 PM BROADWOOD PARTNERS, L.P. 10% Owner Jan 04 '24 Buy 28.91 63,246 1,828,183 10,607,654 Jan 05 07:07 PM BROADWOOD PARTNERS, L.P. 10% Owner Jan 03 '24 Buy 28.93 6,573 190,144 10,544,408 Jan 05 07:07 PM Zhou Lilian Yansheng Director Dec 06 '23 Buy 30.74 850 26,129 2,327 Dec 06 04:11 PM BROADWOOD PARTNERS, L.P. 10% Owner Nov 30 '23 Buy 31.42 177,707 5,583,678 10,537,835 Nov 30 07:08 PM BROADWOOD PARTNERS, L.P. 10% Owner Nov 29 '23 Buy 31.39 160,300 5,031,358 10,360,128 Nov 30 07:08 PM BROADWOOD PARTNERS, L.P. 10% Owner Nov 28 '23 Buy 31.85 96,984 3,088,794 10,199,828 Nov 30 07:08 PM BROADWOOD PARTNERS, L.P. 10% Owner Nov 10 '23 Buy 32.73 34,320 1,123,383 10,102,337 Nov 14 07:13 PM BROADWOOD PARTNERS, L.P. 10% Owner Nov 13 '23 Buy 33.04 507 16,749 10,102,844 Nov 14 07:13 PM BROADWOOD PARTNERS, L.P. 10% Owner Nov 08 '23 Buy 33.71 139,409 4,699,073 9,928,017 Nov 09 07:01 PM BROADWOOD PARTNERS, L.P. 10% Owner Nov 09 '23 Buy 33.09 140,000 4,632,581 10,068,017 Nov 09 07:01 PM BROADWOOD PARTNERS, L.P. 10% Owner Nov 07 '23 Buy 34.03 9,731 331,127 9,788,608 Nov 09 07:01 PM BROADWOOD PARTNERS, L.P. 10% Owner Nov 06 '23 Buy 34.16 164,607 5,623,518 9,778,877 Nov 06 07:01 PM BROADWOOD PARTNERS, L.P. 10% Owner Nov 02 '23 Buy 35.79 144,027 5,155,243 9,613,750 Nov 06 07:01 PM BROADWOOD PARTNERS, L.P. 10% Owner Nov 03 '23 Buy 36.06 520 18,753 9,614,270 Nov 06 07:01 PM BROADWOOD PARTNERS, L.P. 10% Owner Oct 05 '23 Buy 37.92 97,474 3,696,399 9,394,424 Oct 06 07:43 PM BROADWOOD PARTNERS, L.P. 10% Owner Oct 06 '23 Buy 37.62 75,299 2,832,417 9,469,723 Oct 06 07:43 PM BROADWOOD PARTNERS, L.P. 10% Owner Oct 04 '23 Buy 37.93 32,523 1,233,649 9,296,950 Oct 06 07:43 PM Lin Elizabeth Yeu Director Sep 21 '23 Buy 40.00 2,500 100,000 2,855 Sep 22 07:18 PM BROADWOOD PARTNERS, L.P. 10% Owner Sep 21 '23 Buy 39.62 154,814 6,133,467 9,264,427 Sep 21 08:31 PM BROADWOOD PARTNERS, L.P. 10% Owner Sep 20 '23 Buy 40.67 132,079 5,372,274 9,109,613 Sep 21 08:31 PM BROADWOOD PARTNERS, L.P. 10% Owner Sep 19 '23 Buy 40.89 4,490 183,613 8,977,534 Sep 21 08:31 PM
Index -
P/E -
EPS (ttm) -4.26
Insider Own 11.32%
Shs Outstand 13.37M
Perf Week 1.51%
Market Cap 42.65M
Forward P/E -
EPS next Y -1.83
Insider Trans 162.36%
Shs Float 11.86M
Perf Month 6.33%
Income -36.80M
PEG -
EPS next Q -0.46
Inst Own 53.61%
Short Float 1.71%
Perf Quarter 16.00%
Sales 1.02M
P/S 41.81
EPS this Y 39.07%
Inst Trans -23.98%
Short Ratio 5.80
Perf Half Y 6.33%
Book/sh 1.70
P/B 1.88
EPS next Y 19.91%
ROA -44.55%
Short Interest 0.20M
Perf Year -5.34%
Cash/sh 0.69
P/C 4.61
EPS next 5Y -
ROE -101.76%
52W Range 2.08 - 4.34
Perf YTD 27.60%
Dividend Est. -
P/FCF -
EPS past 5Y 14.72%
ROI -145.23%
52W High -26.50%
Beta 1.00
Dividend TTM -
Quick Ratio 1.38
Sales past 5Y 16.25%
Gross Margin -96.14%
52W Low 53.37%
ATR (14) 0.20
Dividend Ex-Date -
Current Ratio 1.38
EPS Y/Y TTM 67.49%
Oper. Margin -2115.74%
RSI (14) 53.93
Volatility 5.21% 6.71%
Employees 46
Debt/Eq 0.16
Sales Y/Y TTM -
Profit Margin -3597.65%
Recom 2.00
Target Price 4.12
Option/Short No / Yes
LT Debt/Eq 0.12
EPS Q/Q 98.33%
Payout -
Rel Volume 0.19
Prev Close 3.05
Sales Surprise -67.36%
EPS Surprise 31.29%
Sales Q/Q -77.54%
Earnings Aug 08 AMC
Avg Volume 35.03K
Price 3.19
SMA20 3.28%
SMA50 2.89%
SMA200 5.44%
Trades
Volume 6,676
Change 4.59%
Date
Action
Analyst
Rating Change
Price Target Change
May-24-22 Downgrade
Stephens
Overweight → Equal-Weight
Mar-14-22 Downgrade
KeyBanc Capital Markets
Overweight → Sector Weight
Jan-07-22 Initiated
Stephens
Overweight
$3.10
Jan-06-22 Resumed
Piper Sandler
Overweight
$3.10
Mar-17-21 Resumed
Needham
Buy
$8
Jan-07-21 Upgrade
The Benchmark Company
Speculative Buy → Buy
$6
Dec-16-20 Upgrade
Piper Sandler
Neutral → Overweight
$2 → $4
Nov-30-20 Initiated
BTIG Research
Buy
$5
Nov-10-20 Initiated
KeyBanc Capital Markets
Overweight
$5
Jul-30-20 Reiterated
The Benchmark Company
Speculative Buy
$7 → $6
Jul-01-20 Downgrade
Piper Sandler
Overweight → Neutral
Jun-30-20 Downgrade
Chardan Capital Markets
Buy → Neutral
$2
Jun-02-20 Initiated
Needham
Buy
$4
Feb-13-19 Initiated
Piper Jaffray
Overweight
$6
Jan-29-19 Upgrade
Janney
Neutral → Buy
Dec-19-18 Resumed
Lake Street
Buy
Show Previous Ratings
Aug-20-24 09:00AM
Aug-12-24 04:10PM
Aug-08-24 04:05PM
Aug-05-24 04:05PM
Aug-01-24 04:05PM
08:00AM
Loading…
Jul-11-24 08:00AM
Jun-24-24 12:41PM
Jun-17-24 04:05PM
Jun-05-24 07:00AM
Jun-03-24 02:13PM
May-30-24 04:47PM
May-15-24 08:55PM
04:05PM
May-13-24 08:00AM
May-07-24 09:19AM
10:52AM
Loading…
Apr-12-24 10:52AM
06:00AM
Apr-11-24 09:46PM
05:30PM
Apr-09-24 04:05PM
Jan-16-24 08:00AM
Dec-06-23 08:00AM
Nov-09-23 08:27AM
07:00AM
Nov-03-23 08:30AM
Sep-18-23 08:00AM
Sep-06-23 08:00AM
Aug-28-23 08:30AM
Aug-10-23 07:00AM
Aug-09-23 08:00AM
08:30AM
Loading…
Aug-08-23 08:30AM
Aug-03-23 08:00AM
Jul-25-23 09:08AM
Jul-24-23 01:35PM
Jun-27-23 08:30AM
Jun-01-23 04:15PM
May-11-23 08:00AM
Apr-27-23 04:59PM
Apr-18-23 08:45AM
Apr-12-23 04:15PM
Apr-07-23 08:24AM
Apr-03-23 08:00AM
Mar-31-23 05:00PM
Mar-29-23 04:01PM
(GlobeNewswire) +5.52%
-8.50%
Mar-15-23 04:01PM
(GlobeNewswire) -20.00%
+51.50%
Mar-02-23 09:00AM
Feb-22-23 08:00AM
Dec-16-22 08:19AM
08:00AM
Nov-30-22 06:05PM
06:00PM
Nov-10-22 04:30PM
Oct-27-22 04:01PM
Oct-06-22 08:00AM
Sep-07-22 08:00AM
Aug-31-22 04:01PM
Aug-30-22 04:27PM
Aug-24-22 08:00AM
Aug-10-22 04:05PM
Aug-03-22 04:01PM
Aug-01-22 11:33AM
05:00AM
Jul-27-22 04:01PM
Jul-13-22 08:00AM
Jul-06-22 08:00AM
Jun-22-22 08:00AM
Jun-15-22 07:15AM
May-26-22 05:00PM
May-11-22 04:05PM
May-05-22 08:00AM
Apr-28-22 04:01PM
Apr-27-22 04:30PM
Apr-22-22 09:26AM
Apr-13-22 10:01PM
05:12PM
05:10PM
Apr-11-22 08:00AM
Mar-28-22 08:00AM
Mar-10-22 04:05PM
(GlobeNewswire) +7.69%
-7.86%
Mar-01-22 04:05PM
Feb-21-22 07:26AM
Feb-10-22 08:00AM
Jan-18-22 04:05PM
(GlobeNewswire) +15.87%
-24.20%
Jan-06-22 09:43AM
Jan-04-22 08:00AM
Dec-09-21 06:00PM
(GlobeNewswire) -9.81%
-6.28%
Dec-08-21 08:00AM
Dec-06-21 08:00AM
Dec-02-21 08:00AM
Nov-22-21 06:14AM
Nov-09-21 04:05PM
Nov-04-21 08:00AM
Nov-02-21 03:02PM
Oct-27-21 08:00AM
Oct-26-21 04:05PM
Oct-08-21 09:46AM
Oct-07-21 08:00AM
Sep-30-21 08:00AM
Sep-20-21 11:35AM
08:00AM
OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Alameda, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
BROADWOOD PARTNERS, L.P. 10% Owner Apr 11 '24 Buy 2.92 2,420,000 7,057,688 4,929,066 Apr 15 07:21 PM Riggs Josh CEO and President Apr 11 '24 Buy 2.95 3,390 10,000 3,505 Apr 15 06:04 AM Arno Andrew Director Apr 11 '24 Buy 2.95 33,898 99,999 69,054 Apr 15 06:02 AM
Index RUT
P/E -
EPS (ttm) -0.13
Insider Own 0.44%
Shs Outstand 188.84M
Perf Week -4.65%
Market Cap 157.87M
Forward P/E -
EPS next Y -0.14
Insider Trans 2.53%
Shs Float 188.00M
Perf Month -3.35%
Income -24.19M
PEG -
EPS next Q -0.04
Inst Own 50.54%
Short Float 8.25%
Perf Quarter -14.69%
Sales 6.19M
P/S 25.50
EPS this Y -7.14%
Inst Trans 0.01%
Short Ratio 23.56
Perf Half Y -26.02%
Book/sh 0.36
P/B 2.31
EPS next Y -11.48%
ROA -22.55%
Short Interest 15.51M
Perf Year -38.07%
Cash/sh 0.20
P/C 4.10
EPS next 5Y -
ROE -34.32%
52W Range 0.77 - 1.61
Perf YTD -23.30%
Dividend Est. -
P/FCF -
EPS past 5Y 19.25%
ROI -34.49%
52W High -48.07%
Beta 1.26
Dividend TTM -
Quick Ratio 2.64
Sales past 5Y 119.78%
Gross Margin 80.04%
52W Low 9.07%
ATR (14) 0.06
Dividend Ex-Date -
Current Ratio 2.64
EPS Y/Y TTM -3.94%
Oper. Margin -413.76%
RSI (14) 41.07
Volatility 6.59% 6.76%
Employees 75
Debt/Eq 0.04
Sales Y/Y TTM -41.22%
Profit Margin -391.00%
Recom 1.43
Target Price 5.00
Option/Short Yes / Yes
LT Debt/Eq 0.03
EPS Q/Q 0.33%
Payout -
Rel Volume 0.57
Prev Close 0.87
Sales Surprise 49.28%
EPS Surprise 33.33%
Sales Q/Q -56.34%
Earnings Aug 08 AMC
Avg Volume 658.42K
Price 0.84
SMA20 -4.81%
SMA50 -11.00%
SMA200 -21.25%
Trades
Volume 376,589
Change -4.02%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-20-24 Initiated
Craig Hallum
Buy
$4
Nov-02-22 Initiated
Robert W. Baird
Outperform
$5
Jun-14-22 Initiated
B. Riley Securities
Buy
$4
Aug-19-21 Initiated
Noble Capital Markets
Outperform
$8
Mar-31-21 Initiated
Cantor Fitzgerald
Overweight
$6
Aug-13-24 08:00AM
Aug-08-24 06:35PM
04:05PM
Aug-01-24 08:00AM
Jul-02-24 08:00AM
08:00AM
Loading…
May-30-24 08:00AM
May-21-24 08:00AM
May-10-24 04:40PM
03:49PM
02:09PM
(Thomson Reuters StreetEvents)
May-09-24 04:01PM
May-06-24 08:00AM
May-02-24 08:00AM
Apr-30-24 08:00AM
Apr-29-24 04:30PM
12:13PM
Loading…
Apr-19-24 12:13PM
Apr-01-24 08:00AM
Mar-18-24 10:31AM
08:00AM
Mar-14-24 03:53PM
Mar-13-24 08:00AM
Mar-11-24 08:00AM
Mar-08-24 04:20PM
Mar-07-24 10:36PM
04:01PM
Feb-29-24 08:00AM
Feb-13-24 08:00AM
Feb-09-24 09:15AM
Feb-06-24 09:15AM
Jan-16-24 08:00AM
08:00AM
Loading…
Dec-18-23 08:00AM
Nov-11-23 04:02PM
Nov-10-23 02:13PM
09:17AM
(Thomson Reuters StreetEvents)
Nov-09-23 04:01PM
Nov-01-23 08:00AM
Oct-24-23 08:00AM
Oct-17-23 05:14PM
Oct-11-23 08:00AM
Oct-05-23 08:00AM
Sep-19-23 08:00AM
Sep-13-23 08:00AM
Sep-11-23 08:00AM
Sep-06-23 09:40AM
08:00AM
Aug-29-23 08:00AM
Aug-13-23 06:39AM
Aug-11-23 09:43AM
(Thomson Reuters StreetEvents)
Aug-10-23 05:15PM
04:01PM
Aug-09-23 08:50AM
Aug-08-23 06:40PM
Aug-03-23 08:00AM
Jul-24-23 08:00AM
May-22-23 08:00AM
May-16-23 12:02PM
May-11-23 05:35PM
04:01PM
May-09-23 08:00AM
May-04-23 06:15PM
08:00AM
Apr-26-23 08:00AM
Apr-18-23 08:00AM
Apr-10-23 07:57PM
Mar-30-23 08:00AM
Mar-28-23 03:57PM
Mar-20-23 08:00AM
Mar-11-23 03:00AM
Mar-10-23 06:33AM
(Thomson Reuters StreetEvents)
Mar-09-23 05:25PM
04:01PM
Mar-06-23 08:00AM
Mar-02-23 09:55AM
08:00AM
Feb-22-23 09:46AM
08:00AM
Feb-08-23 08:00AM
Nov-29-22 08:00AM
Nov-28-22 08:00AM
Nov-17-22 12:00PM
09:45AM
Nov-10-22 06:35PM
04:05PM
Nov-08-22 05:45PM
Nov-03-22 08:00AM
Oct-31-22 08:00AM
Oct-10-22 08:00AM
Oct-04-22 08:00AM
Oct-03-22 08:00AM
07:41AM
Sep-19-22 07:00AM
Aug-15-22 08:00AM
Aug-12-22 09:30AM
02:31AM
Aug-11-22 04:05PM
Aug-08-22 06:05PM
Aug-04-22 08:00AM
Jul-14-22 08:45AM
Jun-02-22 08:00AM
May-16-22 10:25AM
Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Howe Jill Ann Chief Financial Officer Aug 16 '24 Buy 0.89 10,500 9,345 10,500 Aug 19 06:24 PM Culley Brian M President and CEO May 24 '24 Buy 1.05 10,000 10,500 154,842 May 28 09:11 AM BAILEY DON M Director Feb 08 '24 Buy 1.04 96,155 100,001 158,801 Feb 08 07:00 PM BROADWOOD PARTNERS, L.P. Director Feb 06 '24 Buy 1.04 6,730,770 7,000,001 41,666,255 Feb 08 06:58 PM Jayasuriya Anula Director Dec 29 '23 Buy 1.09 10,000 10,900 10,000 Jan 02 07:08 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite